ライフサイエンス出版株式会社

FacebookTwitterInstagram
menu

Japanese Pharmacology & Therapeutics(JPT)

Vol. 26 Suppl. 4 1998

All papers include English abstract **In English

■Preclinical Studies of Mizolastine

A single dose toxicity study of mizolastine in rats and cynomolgus monkeys

M. Bezancon, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s565-71**


A 6-month oral toxicity study of mizolastine in rats

M. Bezancon, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s573-90**


A 6-month oral toxicity study of mizolastine in cynomolgus monkeys

M. Bezancon, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s591-610**


A 12-month oral toxicity study of mizolastine in rats with a recovery period of one month

M. Bezancon, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s611-31**


A 12-month oral toxicity study of mizolastine in cynomolgus monkeys with a recovery period of one month

M. Bezancon, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s633-54**


Antigenicity study of mizolastine

H. Wada, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s655-62


Mutagenicity and clastogenicity studies with mizolastine

Y. Iwase, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s663-72**


Anti-allergic effects of mizolastine

N. Yamada, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s673-9*


Anti-histamine effects of mizolastine

N. Yamada, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s681-5*


Inhibitory effects of mizolastine on the release of mediators and antagonistic effects against mediators

N. Yamada, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s687-94*


Inhibitory effects of mizolastine on cytokine productions

K. Funayama, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s695-9*


Effects of mizolastine on the experimental model of allergic rhinitis in rats

N. Yamada

Jpn Pharmacol Ther 1998 26(Suppl.4) s701-6*


Effects of mizolastine on the experimental model of allergic rhinitis in rats

N. Yamada, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s707-10*


Inhibitory effects of mizolastine on 5-lipoxygenase

K. Sudo, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s711-3*


H1-receptor antagonism of mizolastine on the isolated ileum of the guinea pig

Richard S, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s715-9*


Characterization of mizolastine in radioligand binding studies in vitro

Schoemaker H, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s721-32*


Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat

Pichat P, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s733-8*


Antihistamine action of mizolastine in comparison with that of terfenadine in the dog

Prouteau M, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s739-43*


Metabolites of mizolastine
-Their affinity for H1 receptors and in vivoanti-histamine properties-

Arbilla S, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s745-7*


General pharmacological studies of mizolastine

Y. Watanabe, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s749-67*


Lack of sedative potential of mizolastine, a novel selectiveH1-receptor antagonist, on the sleep wakefulness cycle in rats

Depoortere H.

Jpn Pharmacol Ther 1998 26(Suppl.4) s769-78*


Effects of mizolastine on respiratory function in the rat

Levrier J, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s779-85*


Evaluation of hemodynamic effects of mizolastine following intravenous dosing in anesthetized dogs

Richard S, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s787-800*


Cardiovascular profile of mizolastine, a H1-receptor antagonist and potential anti-allergic agent, in pentobarbital anesthetized Rats

Pierre F

Jpn Pharmacol Ther 1998 26(Suppl.4) s801-5**


Electrocardiographic effects of mizolastine and terfenadine in conscious dogs
-Modifications induced by ketoconazole pretreatment-

Lainee P, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s807-17**


Evaluation of the effects of mizolastine on coagulation factors in rats

Pattano N

Jpn Pharmacol Ther 1998 26(Suppl.4) s819-21**


General pharmacological studies of mizolastine metabolites

Y. Watanabe, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s823-8*


Pharmacokinetic studies of 2-[[1-[1-[(4-fluorophenyl) methyl]-1H-benzimidazol-2-yl]piperidin-4-yl]methylamino]pyrimidin-4(1H)-one(mizolastine)in rats(1)
-Absorption, distribution, metabolism and excretion after single oral or intravenous administration-

N. Hisanaga, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s829-52*


Pharmacokinetic studies of 2-[[1-[1-[(4-fluorophenyl) methyl]-1H-benzimidazol-2-yl] piperidin-4-yl]methylamino]pyrimidin-4(1H)-one(mizolastine)in rats(2)
-Absorption, distribution, metabolism, excretion and effects of mizolastine on hepatic drug metabolizing enzymes after repeated oral administration-

N. Hisanaga, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s853-67*


Pharmacokinetic studies of 2-[[1-[1-[(4-fluorophenyl) methyl]-1H-benzimidazol-2-yl] piperidin-4-yl]methylamino]pyrimidin-4(1H)-one(mizolastine)in rats(3)
-Feto-placental transfer and excretion into milk-

N. Hisanaga, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s869-78*


Pharmacokinetic studies of 2-[[1-[1-[(4-fluorophenyl) methyl]-1H-benzimidazol-2-yl] piperidin-4-yl]methylamino]pyrimidin-4(1H)-one(mizolastine)
-Protein binding in rat, monkey and human-

M. Yamamoto, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s879-87*


Pharmacokinetic studies of mizolastine(2-[[1-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]piperidin-4-yl]methylamino]pyrimidin-4(1H)-one) in cynomolgus monkeys
-Absorption, metabolism and excretion after single administration-

Pouliquen I, et al.

Jpn Pharmacol Ther 1998 26(Suppl.4) s889-901**